**Dr. Braulio Ferreira de Souza Dias**

**Executive Secretary of Convention on Biological Diversity**

Ref.: SCBD/BS/CG/MPM/DA/85327

Dear Sir:

            In response to CBD notification 2016-009 dated 14 January 2016, I would like to submit the information requested in decision on contained use (Article 6 of CPB).

According to National Biosafety Law of the Islamic Republic of Iran, research and contained use at both laboratory and greenhouse are exempted from regulation.

“Article 10: Laboratory and green house researches of living modified organisms and the issues related to pharmaceuticals and their derivatives that have human consumption are not in the scope of this act.” Institutional regulations and monitoring are in place and other relevant international regulations are in use.

Paragraph C of the Article 5 of the National Biosafety Law states that only “RELEASE” of the LMOs AFTER the accomplishment of FIELD TRIALS requires approval. Therefore, field trials are also currently not regulated in Iran. However, there is a growing demand that contained field trials are also regulated; but in a facilitated manner.

Iran gives priority to research and contained use. Researchers are allowed to freely design their experiments as long as there is no possibility of release in the environment prior to proper approval from the relevant authorities as stated in the law.

Please accept sir, the assurances of my highest consideration.

**Behzad Ghareyazie** (PhD Genetics)

CPB NFP (Islamic Republic of Iran)

Director, Research and Technology Directorate,  
Management and Planning Organization, Presidential Office of Iran.  
President, Biosafety Society of Iran.  
President, Agronomy and Plant Breeding Society of Iran,  
Executive Director, Iran Biotechnology Information Center (IRBIC)  
Tel. Office: 0098-2632703536  
Mobile:       0098-9121271496  
Fax:             0098-2634482871  
E-mail:        [ghareyazie@yahoo.com](mailto:ghareyazie@yahoo.com)  
URL:           [www.irbic.ir](http://www.irbic.ir/)